---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000031"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:44:03.680687+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q4 product revenue $339M (+72% YoY); BRUKINSA sales $176M (+101%); tislelizumab gets 10th China approval

## Summary
- Product revenue $339M Q4, $1.3B FY2022, up 72% and 98% YoY; net loss $445M Q4, $2.0B FY.
- BRUKINSA global sales $176M Q4 (+101%), $565M FY (+159%); U.S. sales $125M Q4 (+124%).
- Tislelizumab China sales $102M Q4 (+88%), $423M FY (+66%); NMPA approved 10th indication for first-line gastric cancer.
- Cash $4.5B at Dec 31, 2022; operating cash burn $1.5B FY.
- BRUKINSA received U.S. FDA approval for CLL/SLL in Jan 2023; EC approval for CLL.

## SEC filing metadata
- accession: 0001651308-23-000031
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/bgne-20230224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000031
- JSON: https://secwatch.observer/filing/0001651308-23-000031.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000031.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported full year 2022 results: revenue $1.4 billion.
  - Period: full year 2022
  - Revenue: $1.4 billion
  - Result: reported results
  source text: Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm
- Earnings Releases
  BeOne Medicines Ltd. reported fourth quarter 2022 results: revenue $380.1 million.
  - Period: fourth quarter 2022
  - Revenue: $380.1 million
  - Result: reported results
  source text: Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.